Open AccessPeculiarities of dabigatran pharmacogenetics: literature review
Author(s) -
А. О. Рубаненко,
O. A. Rubanenko,
Yu. V. Shchukin
Publication year - 2022
Publication title -
vestnik aritmologii
Language(s) - English
Resource type - Journals
eISSN - 2658-7327
pISSN - 1561-8641
DOI - 10.35336/va-2022-1-06
Subject(s) - dabigatran , medicine , pharmacogenetics , atrial fibrillation , pulmonary embolism , venous thrombosis , pharmacology , warfarin , thrombosis , anesthesia , chemistry , biochemistry , genotype , gene
Dabigatran is highly effective oral anticoagulant used in patients with atrial fibrillation, venous thrombosis, pulmonary embolism, orthopedic surgery. The most important role in activation and transport of dabigatran play hepatic carboxylesterase-1 (CES-1) and P-glycoprotein. To date were studied different polymorphisms that affect the pharmacokinetics of dabigatran such as rs2244613 (C > A), rs8192935 (T > C) и rs71647871 (G > A), rs1128503 (1236 C > T), rs2032582 (2677 G > T), rs1045642 (3435 C > T) и rs4148738 (G > A) and others. At the same time, there is no need of dabigatran pharmacogenetics testing in routine care. On the other side, existing literature data is often controversial, that’s why future studies are needed to answer the above-mentioned question.